Tris Pharma Reports P-III Clinical Data of Cebranopadol to Treat Moderate-to-Severe Acute Pain
Shots:
- Tris has reported topline data from P-III (ALLEVIATE-2) trial in post-bunionectomy pts, plus additional data from P-III (ALLEVIATE-1) trial in post-abdominoplasty pts. Data from both trials, plus HAP studies will support the US FDA’s NDA filing in 2025
- ALLEVIATE-2 evaluated cebranopadol (400µg QD, PO) vs oxycodone (10mg QID, PO) vs PBO, meeting its 1EP of reduced pain intensity (NRS AUC 2-48hrs.) with higher mean activity than oxycodone. It also met its 2EP, with 57.5% pts avoiding opioid rescue vs 28.4% with PBO
- Adding to topline data (Jan 2025), ALLEVIATE-1 also showed cebranopadol-arm pts required fewer rescue doses vs PBO. P-III results to be presented at future meeting
Ref: Businesswire | Image: Tris Pharma
Related News:- Tris Pharma Reports the P-III (ALLEVIATE-1) Study Results of Cebranopadol to Treat Moderate-to-Severe Acute Pain
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
